GATAD2B and neoplasm: Given that KRAS and MYC are currently therapeutically undruggable genetic alterations found in many tumor types, a greater understanding of the interaction and cooperativity between these oncogenic changes and GATAD2B may open up the exploration of new therapeutic approaches.